Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
IRulya Therapeutics
CONTACT
Lead
IRulya Therapeutics Inc.
A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAM-001 (Inhaled Sirolimus) in Adults with Sarcoidosis Associated Pulmonary Hypertension (SAPH). Approximately 60 participants will receive standard of care plus LAM-001 (inhaled sirolimus) 100 mcg, 200 mcg or placebo by oral inhalation once daily for the first 24 weeks of the study, with approximately 20 participants in each treatment group. Participants who complete the first 24 weeks on treatment and appear to have a favorable benefit-risk profile will be eligible to continue receiving LAM-001 for the remainder of the study (Open-Label Extension Period) for an additional 24 weeks, for a total of up to 48 weeks on treatment. All participants will complete evaluations during a Follow-Up Period of 4 weeks.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
